{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:46:28Z","timestamp":1779291988878,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013066","name":"Key Scientific Research Project of Colleges and Universities in Henan Province","doi-asserted-by":"publisher","award":["20B320048"],"award-info":[{"award-number":["20B320048"]}],"id":[{"id":"10.13039\/501100013066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060327"],"award-info":[{"award-number":["82060327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270225"],"award-info":[{"award-number":["82270225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000163"],"award-info":[{"award-number":["82000163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.exphem.2023.09.004","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T02:08:03Z","timestamp":1695175683000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Genetic mutation signature for relapse prediction in normal karyotype acute myeloid leukemia"],"prefix":"10.1016","volume":"128","author":[{"given":"Lijie","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilei","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li'na","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.09.004_bib0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2023.09.004_bib0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0004","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.3390\/cancers12082242","article-title":"High throughput molecular characterization of normal karyotype acute myeloid leukemia in the Context of the Prospective Trial 02\/06 of the Northern Italy Leukemia Group (NILG)","volume":"12","author":"Salmoiraghi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2023.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.09.004_bib0006","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.09.004_bib0007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.09.004_bib0008","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0009","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/ajt.15654","article-title":"A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Han","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.exphem.2023.09.004_bib0011","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12185-022-03441-6","article-title":"Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1","volume":"116","author":"Han","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0012","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.004_bib0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-019-0158-5","article-title":"Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","article-title":"Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study","volume":"6","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2023.09.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1734156","article-title":"Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma","volume":"9","author":"Peng","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2023.09.004_bib0016","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-021-01126-3","article-title":"Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia","volume":"35","author":"Paiva","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103126","article-title":"Development and validation of a prognostic model for adult patients with acute myeloid leukaemia","volume":"62","author":"Ma","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.exphem.2023.09.004_bib0018","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0019","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41375-018-0148-3","article-title":"A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial","volume":"32","author":"Burnett","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.004_bib0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/jcm9020536","article-title":"Comparison of high-dose cytarabine, mitoxantrone, and pegaspargase (HAM-pegA) to high-dose cytarabine, mitoxantrone, cladribine, and filgrastim (CLAG-M) as first-line salvage cytotoxic chemotherapy for relapsed\/refractory acute myeloid leukemia","volume":"9","author":"Patzke","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.exphem.2023.09.004_bib0021","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bbmt.2017.01.085","article-title":"Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia","volume":"23","author":"Zhu","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2023.09.004_bib0022","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0023","article-title":"A somatic mutation signature predicts the best overall response to anti-programmed cell death protein-1 treatment in epidermal growth factor receptor\/anaplastic lymphoma kinase-negative non-squamous non-small cell lung cancer","volume":"9","author":"Peng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.exphem.2023.09.004_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.778276","article-title":"A support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-PD-1\/PD-L1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer","volume":"12","author":"Peng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.16420","article-title":"Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients","volume":"189","author":"Prieto-Conde","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0026","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/genes12060895","article-title":"DNA methylation signatures predict cytogenetic subtype and outcome in pediatric acute myeloid leukemia (AML)","volume":"12","author":"Krali","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.exphem.2023.09.004_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2020009244","article-title":"Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML","volume":"138","author":"Mulet-Lazaro","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0028","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41409-019-0721-z","article-title":"Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation","volume":"55","author":"Chen","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2023.09.004_bib0029","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/bloodadvances.2021004668","article-title":"Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies","volume":"5","author":"Stengel","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2023.09.004_bib0030","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.1002\/cam4.3467","article-title":"Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.exphem.2023.09.004_bib0031","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/asheducation-2017.1.37","article-title":"Classification and risk assessment in AML: integrating cytogenetics and molecular profiling","volume":"2017","author":"Moarii","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2023.09.004_bib0033","article-title":"Risk stratification of cytogenetically normal acute myeloid leukemia with biallelic CEBPA mutations based on a multi-gene panel and nomogram model","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.09.004_bib0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3892\/ol.2020.12243","article-title":"Immune prognostic risk score model in acute myeloid leukemia with normal karyotype","volume":"20","author":"Dong","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2023.09.004_bib0036","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update measurable residual disease in acute myeloid leukemia: European LeukemiaNet Working Party Consensus Document","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.004_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2023.09.004_bib0038","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2023.09.004_bib0039","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood-2010-08-303479","article-title":"Integrative prognostic risk score in acute myeloid leukemia with normal karyotype","volume":"117","author":"Damm","year":"2011","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2301706X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2301706X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:12:27Z","timestamp":1777547547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2301706X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":39,"alternative-id":["S0301472X2301706X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.09.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic mutation signature for relapse prediction in normal karyotype acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}